Literature DB >> 30665272

County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Amanda J Abraham1, Grace Bagwell Adams2, Ashley C Bradford3, William D Bradford1.   

Abstract

OBJECTIVE: To identify geographic disparities in access to opioid use disorder (OUD) treatment medications and county demographic and economic characteristics associated with access to buprenorphine and oral naltrexone prescribers in Medicare Part D. DATA SOURCES/STUDY
SETTING: We utilized data from the Medicare Part D Prescription Drug Event Standard Analytic File (2010-2015). STUDY DESIGN/DATA COLLECTION: We used logistic regression to examine county-level access to OUD medication prescribers. PRINCIPAL
FINDINGS: There was a 5.6 percentage point increase in counties with access to an OUD prescriber over the study period. However, in 2015, 60 percent of US counties lacked access to a Medicare Part D buprenorphine prescriber and over 75 percent lacked access to an oral naltrexone prescriber. Increased access to OUD prescribers was largely concentrated in urban counties. Results of logistic regression indicate regional differences and potential racial disparities in access to OUD prescribers.
CONCLUSIONS: To improve access to buprenorphine and naltrexone treatment for Medicare Part D enrollees, CMS may consider implementing educational and training initiatives focused on OUD treatment, offering training to obtain a buprenorphine waiver at no cost to providers, and sending targeted information to providers in low OUD treatment capacity areas. © Health Research and Educational Trust.

Entities:  

Keywords:  access; buprenorphine; medicare; naltrexone; opioid use disorder

Mesh:

Substances:

Year:  2019        PMID: 30665272      PMCID: PMC6407357          DOI: 10.1111/1475-6773.13113

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  22 in total

1.  Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

Authors:  Cynthia L Arfken; Chris-Ellyn Johanson; Salvatore di Menza; Charles Roberts Schuster
Journal:  J Subst Abuse Treat       Date:  2010-07-03

2.  Use of Opioid Agonist Therapy for Medicare Patients in 2013.

Authors:  Anna Lembke; Jonathan H Chen
Journal:  JAMA Psychiatry       Date:  2016-09-01       Impact factor: 21.596

3.  The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.

Authors:  Robert Dufour; Ashish V Joshi; Margaret K Pasquale; David Schaaf; Jack Mardekian; George A Andrews; Nick C Patel
Journal:  Pain Pract       Date:  2013-12-01       Impact factor: 3.183

4.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

5.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

6.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

7.  Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment.

Authors:  Bradley D Stein; Mark Sorbero; Andrew W Dick; Rosalie Liccardo Pacula; Rachel M Burns; Adam J Gordon
Journal:  JAMA       Date:  2016-09-20       Impact factor: 56.272

8.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Authors:  Leslie Amass; Walter Ling; Thomas E Freese; Chris Reiber; Jeffrey J Annon; Allan J Cohen; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Cynthia Clark; Douglas M Ziedonis; Jonathan Krejci; Susan Stine; Theresa Winhusen; Greg Brigham; Dean Babcock; Joan A Muir; Betty J Buchan; Terry Horton
Journal:  Am J Addict       Date:  2004

9.  Supply of buprenorphine waivered physicians: the influence of state policies.

Authors:  Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero
Journal:  J Subst Abuse Treat       Date:  2014-08-02

10.  Racial/ethnic minority and low-income hotspots and their geographic proximity to integrated care providers.

Authors:  Erick G Guerrero; Dennis Kao
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-09-23
View more
  10 in total

1.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

2.  Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999-2018.

Authors:  Megan S Schuler; Terry L Schell; Eunice C Wong
Journal:  Drug Alcohol Depend       Date:  2021-02-13       Impact factor: 4.492

3.  The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.

Authors:  Hannah K Knudsen; Jeanie Hartman; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2022-01-29       Impact factor: 4.492

4.  Demographic and Geospatial Analysis of Buprenorphine and Methadone Prescription Rates.

Authors:  Nicholas J Peterman; Peggy Palsgaard; Aksal Vashi; Tejal Vashi; Bradley D Kaptur; Eunhae Yeo; Warren Mccauley
Journal:  Cureus       Date:  2022-05-30

5.  Buprenorphine Waiver Attitudes Among Primary Care Providers.

Authors:  Benjamin Lai; Ivana Croghan; Jon O Ebbert
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

6.  Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.

Authors:  Alexandra Savinkina; Rajapaksha W M A Madushani; Golnaz Eftekhari Yazdi; Jianing Wang; Joshua A Barocas; Jake R Morgan; Sabrina A Assoumou; Alexander Y Walley; Benjamin P Linas; Sean M Murphy
Journal:  Addiction       Date:  2022-04-12       Impact factor: 7.256

7.  Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017.

Authors:  Megan S Schuler; Andrew W Dick; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-04-20       Impact factor: 4.852

8.  Place, poverty and prescriptions: a cross-sectional study using Area Deprivation Index to assess opioid use and drug-poisoning mortality in the USA from 2012 to 2017.

Authors:  Shaheen Kurani; Rozalina Grubina McCoy; Jonathan Inselman; Molly Moore Jeffery; Sagar Chawla; Lila J Finney Rutten; Rachel Giblon; Nilay D Shah
Journal:  BMJ Open       Date:  2020-05-17       Impact factor: 2.692

9.  Projected Estimates of Opioid Mortality After Community-Level Interventions.

Authors:  Benjamin P Linas; Alexandra Savinkina; R W M A Madushani; Jianing Wang; Golnaz Eftekhari Yazdi; Avik Chatterjee; Alexander Y Walley; Jake R Morgan; Rachel L Epstein; Sabrina A Assoumou; Sean M Murphy; Bruce R Schackman; Stavroula A Chrysanthopoulou; Laura F White; Joshua A Barocas
Journal:  JAMA Netw Open       Date:  2021-02-01

Review 10.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.